DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Soliqua 100 is a drug marketed by Sanofi-aventis Us and is included in one NDA. There are twenty-six patents protecting this drug.
The generic ingredient in SOLIQUA 100 is insulin glargine; lixisenatide. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin glargine; lixisenatide profile page.
Soliqua 100 was eligible for patent challenges on December 31, 1968.